About Atomoxetine Hydrochloride API
Therapeutic CategoryCentral Nervous System (CNS)
CAS Number
82248-59-7
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Canada DMF
Mechanism of Action
The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.
Indication
STRATTERA is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Related APIs
Atomoxetine Hydrochloride
Central Nervous System (CNS)
Benztropine Mesylate
Central Nervous System (CNS)
Dimethyl Fumarate
Central Nervous System (CNS)
Edaravone
Central Nervous System (CNS)
Eslicarbazepine Acetate
Central Nervous System (CNS)
Eszopiclone
Central Nervous System (CNS)
Levetiracetam
Central Nervous System (CNS)
Lumateperone Tosylate
Central Nervous System (CNS)
Lurasidone Hydrochloride
Central Nervous System (CNS)
Memantine Hydrochloride
Central Nervous System (CNS)
Pregabalin
Central Nervous System (CNS)
Rimegepant
Central Nervous System (CNS)
Risperidone
Central Nervous System (CNS)
Rivastigmine Hydrogen Tartrate
Central Nervous System (CNS)
Ropinirole Hydrochloride
Central Nervous System (CNS)
Sugammadex Sodium
Central Nervous System (CNS)
Tizanidine Hydrochloride
Central Nervous System (CNS)
Xanomeline
Central Nervous System (CNS)
Fluoxetine
Central Nervous System (CNS)
Quetiapine Fumarate
Central Nervous System (CNS)
Apremilast (form B)
Central Nervous System (CNS)
Donepezil Hydrochloride
Central Nervous System (CNS)
Siponimod Hemifumarate
Central Nervous System (CNS)
Ziprasidone Hydrochloride Anhydrous
Central Nervous System (CNS)
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
Treats attention deficit hyperactivity disorder (ADHD) by increasing attention and reducing hyperactivity and impulsiveness
-
It is a oncology product used to treat Metastatic castration-resistant prostate cancer (CRPC). Metastatic high-risk castration-sensitive prostate cancer (CSPC)
-
Available as oral capsules: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg
-
Store at 20°C to 25°C (68°F to 77°F), in a tightly closed container, protect from moisture
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.